Responding to NICE's consultation on enzalutamide


2. First you need to tell NICE who you are by filling in some details here.

You'll be asked for the following information:

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation 2 document

Please enter your contact details before submitting your comments on this document:

Your Name:

Your Email Address: The Institute may wish to contact you, if we do it will be by e-mail, so please make sure that the e-mail address you submit is correct.

Confirm Email Address:

Your role: Select your role below:

Other Role:

Your location:

Conflict of Interest?: Do you work for, or are projects you work on funded by, the manufacturers of this technology?

Yes, No

Notes: Is there anything else of relevance you wish to disclose?

Please note that information provided may be made available to NICE staff involved in this consultation.

Data Protection: The information you submit on this form will be retained and used by the NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties. Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted. The information may appear on the Institute's website in due course in which case all personal data will be removed in accordance with NICE policies.

By submitting your data on this website you are confirming that you have read and understood this statement and accept that personal information, including sensitive data, sent to us will be retained and used for the purposes and in the manner specified above and in accordance with the Data Protection Act 1998.

Submit
3. There are then opportunities to comment on different aspects of the appraisal – such as how the evidence was considered or the manufacturer’s submission. You can either respond under whichever headings you want to, or add all your comments under the first section here. It may be easier to write what you want to say in a word document, then copy and paste it into the box.

1 Appraisal Committee’s preliminary recommendations

1.1 Enzalutamide is recommended as an option for treating hormone-relapsed metastatic prostate cancer in adults, only if:
   • their disease has progressed during or after docetaxel-containing chemotherapy and they have not had treatment with abiraterone
   and
   • the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.

Comment on Section 1: Appraisal Committee’s preliminary recommendations

Please share with NICE how this decision will affect you or those you know.

Here’s what we’re saying to NICE.

- It’s good that enzalutamide has been approved – it’s an effective drug and we want it to be available to men with advanced prostate cancer.
- This restriction is bad news for men who already have limited treatment options – abiraterone is the only other drug available to them.
- This complicates the situation for men at an already difficult time.
- This makes the decision very difficult for clinicians, as enzalutamide and abiraterone work differently and doctors can’t tell in advance which will work better for which men.
- The Scottish Medicines Consortium looked at the same evidence and have approved enzalutamide without this restriction.